non-hodgkin's%20lymphoma
NON-HODGKIN'S LYMPHOMA

Non-Hodgkin's lymphoma is a heterogeneous group of lymphoproliferative malignancies.
It is the most common hematologic cancer.
The most common subtypes are the diffuse large B-cell and follicular lymphoma. The subtypes are based on the malignant cell's morphology, genetic features, immunohistological characteristics, and stage of maturation.

Introduction

  • The most common hematologic cancer
  • B-cell non-Hodgkin's lymphoma (NHL) are 80-85% more common than T-cell/NK cell NHLs (15-20%)
  • Advances in molecular genetics allowed better understanding of the pathophysiology & further identification of the different subtypes of NHL
  • NHL subtypes are based on the malignant cell's morphology; genetic features, immunohistological characteristics & stage of maturation

Definition

  • A heterogenous group of lymphoproliferative malignancies formed by either B-cells or T-cell/natural killer (NK) cells

Etiology

Causes of Non-Hodgkin's Lymphoma (NHL)
  • Genetic aberrations & lesions
    • p53 tumor suppressor gene deletions/alterations (eg Burkitt lymphoma, follicular lymphoma, mantle cell lymphoma)
    • Chromosomal deletions (eg chromosome 6q, chromosome 13q14)
    • Chromosomal translocations (eg follicular lymphoma - t[14;18][q32;q21], MCL - t[11;14][q13;q32])
  • Oncogenic viruses (eg Epstein-Barr virus, Human T cell lymphotropic virus I, Human Herpes virus-8)

Signs and Symptoms

Clinical Evaluation
  • Assess patient’s performance status based on the clinical presentation
  • Systemic B-cell symptoms
    • Present in aggressive types of NHLs
    • Fever
    • Night sweats
    • Weight loss
  • Indolent types of NHL
    • Splenomegaly
    • Hepatomegaly
    • Lymphadenopathy
    • Cytopenia
  • Nonspecific signs & symptoms
    • Skin rash
    • Generalized fatigue
    • Fever of unknown origin
    • Pleural effusion
    • Pruritus
    • Malaise
    • Ascites
  • Lymphoma with gastrointestinal tract involvement
    • Anorexia
    • Weight loss
    • Bloatedness
    • Pallor
    • Nausea/vomiting
    • Abdominal pain
    • Early satiety
    • Intestinal bleeding
  • Lymphoma with central nervous system involvement
    • Headache
    • Blurred vision
    • Paralysis
    • Dizziness
    • Seizures
    • Focal neurologic symptoms
  • Adult T-cell leukemia/lymphoma
    • Lymphadenopathy
    • Fatigue
    • Anorexia
    • Splenomegaly
    • CNS involvement
    • Pulmonary complications
    • Skin eruptions
    • Abdominal pain
    • Hepatomegaly
    • Bone marrow involvement
  • Burkitt lymphoma
    • Bone marrow (70%) involvement
    • Leptomeningeal CNS involvement (40%)
  • Extranodal NK/T-cell lymphomas, nasal type
    • Nasal obstruction
    • Nasal bleeding secondary to mass lesion
    • Elevated LDH levels

Risk Factors

  • Acquired immunosuppression (previous organ/bone marrow/stem cell transplant, HIV, AIDS)
  • Congenital immunodeficiency syndromes
  • Old age
  • Positive family history of NHL
  • Positive medical history of Hodgkin lymphoma
  • Chemical exposures (pesticides, wood dust, epoxy glue, organic solvents, medication [eg Methotrexate, TNF-α inhibitors])
  • Radiation exposure
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Dr. Rose Zhao-Wei Ting, 16 Nov 2016
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Elvira Manzano, Roshini Claire Anthony, 14 hours ago
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.